ImaRx Cancels IPO

ImaRx Therapeutics Inc., a Tucson, Ariz.-based drug company using nanotech therapies for stroke and cancer, has withdrawn registration for a $75 million IPO, due to “unfavorable market conditions.” It had planned to trade on the Nasdaq, with CIBC World Markets serving as lead underwriter. Edison Moore Healthcare Ventures is a 7% stakeholder.< ?xml:namespace prefix = o ns = "urn:schemas-microsoft-com:office:office" />